---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-21-000058"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2021-11-23T23:59:59+00:00"
generated_at: "2026-06-28T05:46:42.678854+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q2 FY2022 revenue $7.85B (+2% organic), non-GAAP EPS $1.32; lowers FY revenue growth view

## Summary
- Revenue $7.847B (+3% reported, +2% organic); GAAP EPS $0.97, non-GAAP EPS $1.32.
- Organic growth: Cardiovascular +3%, Medical Surgical flat (ex-ventilators +6%), Neuroscience +3%, Diabetes +1%.
- Lowers FY22 organic revenue growth guidance to 7-8% from ~9% due to COVID-19 and labor shortages.
- Reiterates FY22 non-GAAP EPS guidance $5.65-$5.75; FX revenue benefit reduced to $0-50M from $100-200M.
- Diabetes pump sales grew high-teens US, low-twenties international; CGM sales low-single digits.

## SEC filing metadata
- accession: 0001613103-21-000058
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2021-11-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310321000058/0001613103-21-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310321000058/mdt-20211123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-21-000058
- JSON: https://secwatch.observer/filing/0001613103-21-000058.json
- Plain text: https://secwatch.observer/filing/0001613103-21-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.